Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nalfurafine - Toray

Drug Profile

Nalfurafine - Toray

Alternative Names: AC-820; MT-9938; Nalfurafine hydrochloride; Nopicor; REMITCH; SSS-33; TRK-820; Winfuran

Latest Information Update: 16 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toray
  • Developer Fresenius Medical Care; Japan Tobacco; Maruho; Sansheng Pharmaceutical; SK Chemicals; Toray; Torii Pharmaceutical
  • Class Antipruritics; Morphinans; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pruritus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pruritus
  • Discontinued Atopic dermatitis; Cancer pain; Neuropathic pain

Most Recent Events

  • 16 Sep 2019 Phase-I clinical trials in Pruritus in China (PO) prior to September 2019 (3SBio pipeline, September 2019)
  • 18 Jan 2019 Meiji Seika Pharma acquires the development and commercialisation rights to nalfurafine in Thailand and Indonesia
  • 16 Jan 2018 Sansheng Pharmaceutical acquires the development and commercialisation rights to nalfurafine in China (excluding Hong Kong, Macau and Taiwan)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top